Brian Woodcock v. Correct Care Solutions, LLC

CourtCourt of Appeals for the Sixth Circuit
DecidedJuly 6, 2021
Docket20-5170
StatusUnpublished

This text of Brian Woodcock v. Correct Care Solutions, LLC (Brian Woodcock v. Correct Care Solutions, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Brian Woodcock v. Correct Care Solutions, LLC, (6th Cir. 2021).

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 21a0313n.06

No. 20-5170

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT

FILED ) Jul 06, 2021 BRIAN WOODCOCK, et al., ) DEBORAH S. HUNT, Clerk ) Plaintiffs-Appellants, ) v. ) ON APPEAL FROM THE ) UNITED STATES DISTRICT ) COURT FOR THE EASTERN CORRECT CARE SOLUTIONS, et al., ) DISTRICT OF KENTUCKY ) Defendants-Appellees. )

BEFORE: BATCHELDER, GRIFFIN, and STRANCH, Circuit Judges.

BATCHELDER, J., delivered the opinion of the court in which GRIFFIN, J., joined. STRANCH, J. (pp. 13–22), delivered a opinion concurring in part and dissenting in part.

ALICE M. BATCHELDER, Circuit Judge. In this class action brought pursuant to

42 U.S.C. § 1983, approximately 1,200 Kentucky inmates with Hepatitis C Virus (HCV)

(“Plaintiffs”) sued eight defendants who manage the Kentucky prison system’s HCV-treatment

program (“Defendants”). Plaintiffs claim that by triaging the HCV cure for the most seriously

affected inmates, Defendants were deliberately indifferent to their serious medical needs, in

violation of the Eighth and Fourteenth Amendments. The district court granted summary judgment

for Defendants, holding that Defendants adequately treated Plaintiffs. We AFFIRM. No. 20-5170, Woodcock v. Correct Care Solutions

I. FACTS & PROCEDURAL HISTORY

A. Hepatitis C Virus

HCV is a bloodborne virus commonly spread by sharing contaminated needles, using

unsterilized tattoo equipment, and engaging in sexual behavior. The most common HCV

symptoms range from fatigue and jaundice to severe inflammation, skin lesions, and cognitive

impairment. HCV is categorized as either acute or chronic. In the acute phase, HCV does not

cause noticeable symptoms and some people clear the virus from their systems within six to twelve

months. Those who do not clear the virus suffer from chronic HCV.1 In the chronic phase, HCV

is progressive and attacks the liver, which, over time, causes scarring or fibrosis. The rate at which

the virus causes scarring varies from person to person. Some people might not develop scarring

for 20 to 30 years, while others might suffer accelerated scarring. Between 20 and 40 percent of

people who have chronic HCV eventually develop cirrhosis, which is a severe condition causing

the liver’s affected areas to stop functioning.

There is no vaccine for HCV. In years past, doctors treated the virus with an injectable

medication called interferons. This treatment is marginally effective; it requires that patients stay

sober, causes several unpleasant side effects, and has a success rate of 30 percent. Fortunately, in

2011, the FDA approved a new class of drugs called direct-acting antivirals (DAAs), which cure

nearly all the HCV patients who take them. But the treatment comes at a price; a single course of

treatment costs between $13,000 and $32,000.

1 Medication is necessary to cure chronic HCV. -2- No. 20-5170, Woodcock v. Correct Care Solutions

B. HCV in Kentucky State Prisons

HCV infects about one percent of the United States population, but it is far more prevalent

in prisons. The Kentucky Department of Corrections (KDOC) estimates that about 1,200 of its

12,000 inmates have HCV.

In 2015, the KDOC implemented a new “HCV Treatment Plan,” which it updated in 2017,

2018, and 2020. This HCV Treatment Plan mostly mimics the Federal Bureau of Prison’s HCV

treatment protocol. The 2018 version of the HCV Treatment Plan is at issue in this appeal and has

several components, ranging from inmate screening to DAA treatment.

First, the KDOC screens its inmates for HCV. It obtains all inmates’ health history and

tests for antibodies inmates who (1) have certain clinical conditions such as a reported history of

HCV or elevated levels of Alanine Aminotransferase (ALT), (2) have risk factors such as blood-

transfusion treatment or sharing needles and tattoo guns, or (3) request HCV testing.

If an inmate tests positive for HCV antibodies, the KDOC (1) evaluates the inmate for signs

and symptoms of liver disease, (2) obtains additional laboratory tests, (3) calculates the inmate’s

APRI score (which is used to assess the degree of liver fibrosis, if any), (4) offers vaccines for

hepatitis A, influenza, and pneumococcal, and (5) educates the inmate about chronic HCV.

Finally, the KDOC places each infected inmate into one of three priority groups based on

several factors. Inmates placed in priority level one, the highest level, have an APRI score of

above 2.0 and/or other comorbid medical conditions that warrant immediate treatment. Inmates

with APRI scores between .07 and 2.0 and those with advanced fibrosis, diabetes, liver disease, or

kidney disease comprise priority level two. The KDOC places all other infected inmates in level

three. There are, however, exceptions to the priority-level treatment system. For example, an

-3- No. 20-5170, Woodcock v. Correct Care Solutions

inmate in priority level three may receive DAAs before a priority-level-one inmate if he or she

exhibits an urgent medical need.

Infected inmates are monitored and reevaluated every three to six months, depending on

their health status. As part of the inmate’s individualized care, KDOC Regional Medical Director,

Dr. Frederick Kemen, subject to his medical judgment, might order further testing as he deems

necessary, such as HCV genotyping or a FibroScan2 of the inmate’s liver.

Before 2020, the HCV Treatment Plan required that HCV-infected inmates qualify for

DAA treatment. For example, an inmate is disqualified from receiving treatment if, among other

things, he or she (1) has a life expectancy of fewer than eighteen months, (2) had finished DAA

treatment and has since been reinfected with HCV, (3) had demonstrated an unwillingness or

inability to adhere to rigorous medication regimens, or (4) did not have a clear conduct record for

twelve months before treatment (i.e., no positive drug tests, prison tattoos, nor inappropriate sexual

behavior).

C. Procedural History

The named Plaintiffs are inmates in KDOC prisons who have been diagnosed with HCV.

Brian Woodcock is housed at the Kentucky State Penitentiary (KSP) and has been cured of HCV.

Keath Bramblett, another inmate at KSP, contracted HCV during incarceration and has since been

cured. Ruben Rios Salinas is housed at KSP and has been diagnosed with HCV but was denied

2 A HCV genotype test determines the specific subtype of the virus to help guide a medical provider’s treatment of the patient. See Hepatitis C Genotypes, U.S. Dep’t of Veterans Aff., https://www.hepatitis.va.gov/hcv/background/genotypes.asp. A FibroScan is a noninvasive test that uses ultrasound technology to determine the degree of a patient’s liver fibrosis. Understanding your FibroScan Results, Mem’l Sloane Kettering Cancer Ctr. (Feb. 27, 2018), https://www.mskcc.org/cancer-care/patient-education/understanding-your-fibroscan-results/. -4- No. 20-5170, Woodcock v. Correct Care Solutions

DAA treatment. And Jessica Lawrence has been diagnosed with HCV but has not received DAA

treatment.

Defendants are various persons or entities charged with formulating and managing the

HCV Treatment Plan and each person is sued in his or her individual capacity. Rodney Ballard

and LaDonna Thompson are former KDOC Commissioners.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Watson v. City of Memphis
373 U.S. 526 (Supreme Court, 1963)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
University of Texas v. Camenisch
451 U.S. 390 (Supreme Court, 1981)
Smith v. Wade
461 U.S. 30 (Supreme Court, 1983)
Lewis v. Continental Bank Corp.
494 U.S. 472 (Supreme Court, 1990)
Hudson v. McMillian
503 U.S. 1 (Supreme Court, 1992)
Chafin v. Chafin
133 S. Ct. 1017 (Supreme Court, 2013)
Juana Villegas v. The Metro. Gov't of Nashville
709 F.3d 563 (Sixth Circuit, 2013)
Genesis HealthCare Corp. v. Symczyk
133 S. Ct. 1523 (Supreme Court, 2013)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)
Ford v. County of Grand Traverse
535 F.3d 483 (Sixth Circuit, 2008)
Demis v. Sniezek
558 F.3d 508 (Sixth Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Brian Woodcock v. Correct Care Solutions, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/brian-woodcock-v-correct-care-solutions-llc-ca6-2021.